April 24, 2008 - Boston Scientific Corp. completed enrollment in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT), engineered to test whether CRT-Ds can slow the progression of heart failure in heart attack survivors and in those with other forms of impaired heart function.
The trial includes 1,820 patients and examines the potential benefits of Boston Scientific cardiac resynchronization therapy defibrillators (CRT-Ds) in a new population of heart failure patients. It is the latest in a series of landmark randomized clinical trials sponsored by Boston Scientific's Cardiac Rhythm Management group, following in the tradition of MADIT, MADIT II and COMPANION.
MADIT-CRT may also demonstrate if earlier intervention with CRT-D therapy can slow a patient's progression from early-stage heart failure (as defined by the New York Heart Association as Class I and II) to late-stage heart failure (Class III and IV).
"This study builds on the observations made in the COMPANION trial, which evaluated the benefits of CRT-D therapy in patients with late-stage, symptomatic heart failure," said Arthur Moss, M.D., Professor of Medicine at the University of Rochester, NY, and Principal Investigator of MADIT-CRT. "If positive, this trial may address the still unanswered question about the potential of resynchronization defibrillator therapy to inhibit the clinical progression of heart failure through earlier intervention."
Approximately 70 percent of all heart failure patients fall into Class I or II. Nearly 22 million people worldwide, including approximately 5.5 million Americans, currently suffer from some form of heart failure. Nearly one million new cases of heart failure are diagnosed annually worldwide, making it the most rapidly growing cardiovascular disorder.
For more information: www.bostonscientific.com
May 18, 2024 
